Evidence map›Paper›PMID 38232730›Full record

ArticleAmerican journal of human genetics2024

Neuronal MAPT expression is mediated by long-range interactions with cis-regulatory elements.

Brianne B Rogers, Ashlyn G Anderson, Shelby N Lauzon, M Natalie Davis, Rebecca M Hauser, Sydney C Roberts, Ivan Rodriguez-Nunez, Katie Trausch-Lowther, Erin A Barinaga, Paige I Hall and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Promoter mutagenesis and a massively parallel reporter screen of thebioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

  • Update of
    2023
5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Brianne B RogersHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA; University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Ashlyn G AndersonHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Shelby N LauzonHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
M Natalie DavisHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Rebecca M HauserHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Sydney C RobertsHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Ivan Rodriguez-NunezHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Katie Trausch-LowtherHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Erin A BarinagaHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Paige I HallHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Matthew T KnueselHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Jared W TaylorHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Mark MackiewiczHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Brian S RobertsHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Sara J CooperHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Lindsay F RizzardiHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Richard M MyersHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA. Electronic address: rmyers@hudsonalpha.org.
J Nicholas CochranHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA. Electronic address: ncochran@hudsonalpha.org.
HudsonAlpha Institute for Biotechnology · USUniversity of Alabama at Birmingham · US

Funding

UAB Research Training Program in Neurobiology of Cognition and Cognitive DisordersT32NS061788 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Farah Dominique Lubin · 2008 to 2026
$4.5M
Regulatory mechanisms of rare non-coding variation in neurodegeneration-associated lociR00AG068271 · NIA · HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY · PI COCHRAN, JESSE N · 2021 to 2023
$725k
Regulatory mechanisms of rare non-coding variation in neurodegeneration-associated lociK99AG068271 · NIA · HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY · PI COCHRAN, JESSE N · 2020 to 2020
$118k
NIA NIH HHS K99 AG068271NIA NIH HHS R00 AG068271NINDS NIH HHS T32 NS061788
6 · The paper itself

Abstract

Tauopathies are a group of neurodegenerative diseases defined by abnormal aggregates of tau, a microtubule-associated protein encoded by MAPT. MAPT expression is near absent in neural progenitor cells (NPCs) and increases during differentiation. This temporally dynamic expression pattern suggests that MAPT expression could be controlled by transcription factors and cis-regulatory elements specific to differentiated cell types. Given the relevance of MAPT expression to neurodegeneration pathogenesis, identification of such elements is relevant to understanding disease risk and pathogenesis. Here, we performed chromatin conformation assays (HiC & Capture-C), single-nucleus multiomics (RNA-seq+ATAC-seq), bulk ATAC-seq, and ChIP-seq for H3K27ac and CTCF in NPCs and differentiated neurons to nominate candidate cis-regulatory elements (cCREs). We assayed these cCREs using luciferase assays and CRISPR interference (CRISPRi) experiments to measure their effects on MAPT expression. Finally, we integrated cCRE annotations into an analysis of genetic variation in neurodegeneration-affected individuals and control subjects. We identified both proximal and distal regulatory elements for MAPT and confirmed the regulatory function for several regions, including three regions centromeric to MAPT beyond the H1/H2 haplotype inversion breakpoint. We also found that rare and predicted damaging genetic variation in nominated CREs was nominally depleted in dementia-affected individuals relative to control subjects, consistent with the hypothesis that variants that disrupt MAPT enhancer activity, and thereby reduced MAPT expression, may be protective against neurodegenerative disease. Overall, this study provides compelling evidence for pursuing detailed knowledge of CREs for genes of interest to permit better understanding of disease risk.

Indexed as

Neurodegenerative Diseasestau ProteinsChromatinHaplotypesHumansNeuronsRegulatory Sequences, Nucleic AcidChromatinMAPT protein, humantau ProteinsAlzheimer diseaseenhancergene regulationMAPTneuron

Identifiers

PMID38232730
PMCPMC10870142
OpenAlexW4390989082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.